Nanogen Awarded Contract from the Space and Naval Warfare System Center San Diego

Aug 01, 2000, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, Aug. 1 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) today
 announced that it has been awarded a contract by the Space and Naval Warfare
 Systems Center San Diego (SSC San Diego) in an amount totaling approximately
 $1.6 million over the next two years.
     The contract award was made by SSC San Diego under the Defense Advanced
 Research Projects Agency (DARPA) sponsored BioFluidic Chips (BioFlips) and
 Simulation Tools for Chemical/Biological Microsystems Program.  The objective
 of the DARPA contract is to develop and refine electronically driven sample
 preparation protocols on specifically designed microelectronic chips.  The
 intended samples will simulate a panel of biowarfare related agents found in
 blood.  Pursuant to the contract, extracted DNA from the microelectronic chips
 will be processed for detection using Nanogen's electronic hybridization
     "We are very pleased to have been accepted as a recipient of this contract
 award," commented Howard Birndorf, Chairman, Chief Executive Officer and
 President of Nanogen.  "The electronically-driven sample preparation chip will
 enable Nanogen to expand upon our electronic hybridization technology and move
 closer towards an automated sample-to-answer system for DNA diagnostics.  We
 believe Nanogen's technology may lead to important advances in biological
 warfare defense, in addition to our core focus in the medical research,
 medical diagnostics and forensic areas."
     Nanogen recently began marketing its NanoChip(TM) system to scientists and
 genomics laboratories setting new standards for SNP scoring.  The NanoChip(TM)
 system has been shown to provide accuracy equal to or better than DNA
 sequencing and other methods for SNP confirmation.  Unlike other systems, the
 NanoChip(TM) system uses electronically accelerated hybridization under very
 low salt conditions, potentially avoiding problems with DNA conformation and
 secondary structures, whereas most sequencing and primer extension
 technologies require high salt conditions.  The NanoChip(TM) system allows the
 user to array and analyze DNA on its NanoChip(TM) cartridges in user selected
 formats in a single day with walk-away automation.  The NanoChip(TM) system
 integrates advanced microelectronics and molecular biology into a platform
 technology with broad commercial applications in the fields of biomedical
 research, genomics, medical diagnostics, genetic testing and drug discovery.
 The Company has established corporate alliances as part of its strategy to
 expand the applications and accelerate the commercialization of products
 derived from its technology.
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 contract's research and goals will be achieved, whether the Company's
 NanoChip(TM) system can be or will be further successfully commercialized,
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K, as amended, for
 the year ended December 31, 1999 and subsequent reports filed with the
 Securities and Exchange Commission.  These forward-looking statements speak
 only as of the date hereof.  The Company disclaims any intent or obligation to
 update these forward-looking statements.
     CONTACT:  Kieran T. Gallahue, Senior Vice President and Chief Financial
               Officer, 858-410-4600, of Nanogen; or Media, Page Sargisson of
               Noonan/Russo Communications, 415-677-4455, ext. 229

SOURCE Nanogen, Inc.